These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21155586)

  • 1. Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.
    Knepp AM; Grunbeck A; Banerjee S; Sakmar TP; Huber T
    Biochemistry; 2011 Feb; 50(4):502-11. PubMed ID: 21155586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).
    Garcia-Perez J; Rueda P; Alcami J; Rognan D; Arenzana-Seisdedos F; Lagane B; Kellenberger E
    J Biol Chem; 2011 Sep; 286(38):33409-21. PubMed ID: 21775441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor.
    Abrol R; Trzaskowski B; Goddard WA; Nesterov A; Olave I; Irons C
    Proc Natl Acad Sci U S A; 2014 Sep; 111(36):13040-5. PubMed ID: 25157173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
    Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
    Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
    Latinovic O; Schneider K; Szmacinski H; Lakowicz JR; Heredia A; Redfield RR
    Antiviral Res; 2014 Dec; 112():80-90. PubMed ID: 25453341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.
    Ketas TJ; Kuhmann SE; Palmer A; Zurita J; He W; Ahuja SK; Klasse PJ; Moore JP
    Virology; 2007 Aug; 364(2):281-90. PubMed ID: 17428518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
    Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
    J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 adopts three homodimeric conformations that control cell surface delivery.
    Jin J; Momboisse F; Boncompain G; Koensgen F; Zhou Z; Cordeiro N; Arenzana-Seisdedos F; Perez F; Lagane B; Kellenberger E; Brelot A
    Sci Signal; 2018 May; 11(529):. PubMed ID: 29739880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homogeneous time-resolved fluorescence assay to probe folded G protein-coupled receptors.
    Knepp AM; Sakmar TP; Huber T
    Methods Enzymol; 2013; 522():169-89. PubMed ID: 23374186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR analyses of the interaction between CCR5 and its ligand using functional reconstitution of CCR5 in lipid bilayers.
    Yoshiura C; Kofuku Y; Ueda T; Mase Y; Yokogawa M; Osawa M; Terashima Y; Matsushima K; Shimada I
    J Am Chem Soc; 2010 May; 132(19):6768-77. PubMed ID: 20423099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
    Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
    J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
    Asin-Milan O; Sylla M; El-Far M; Belanger-Jasmin G; Haidara A; Blackburn J; Chamberland A; Tremblay CL
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7565-9. PubMed ID: 25267674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study.
    Kothandan G; Gadhe CG; Cho SJ
    PLoS One; 2012; 7(3):e32864. PubMed ID: 22479344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
    Hu Q; Huang X; Shattock RJ
    J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human.
    Napier C; Sale H; Mosley M; Rickett G; Dorr P; Mansfield R; Holbrook M
    Biochem Pharmacol; 2005 Dec; 71(1-2):163-72. PubMed ID: 16298345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
    Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
    J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
    Appiah-Kubi P; Iwuchukwu EA; Soliman MES
    J Biomol Struct Dyn; 2022; 40(23):13115-13126. PubMed ID: 34569417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.